20 results about "B-cell receptor" patented technology

To provide a gene testing method and a gene testing kit for analyzing a variable region of a TCR or a BCR in single-cell analysis.SOLUTION: A method including a step of capturing mRNA eluted from a single cell using an RT probe immobilized on a solid-phase surface and including a common sequence, a cell identification barcode, a first molecular identification barcode, and an oligo(dT) sequence, a step of performing a reverse transcription reaction in a reverse transcription reaction solution containing a TSO using the mRNA as a template to generate cDNA having a sequence added to a 3' end, a step of degrading the mRNA, a step in which a primer for inserting a second molecular identification barcode binds to a constant region adjacent to a variable region of a TCR or a BCR and includes the second molecular identification barcode, a step of ligating cDNA extended from the primer with a ligase, a step of amplifying a fragment including the second molecular identification barcode and the variable region of the TCR or the BCR using a primer, a step of performing sequence analysis, and a step of associating sequences.SELECTED DRAWING: Figure 2

The invention provides a rabbit-source BCR sequence primer group based on high-throughput single cell V (D) J sequencing and application of the rabbit-source BCR sequence primer group. The primer group comprises a specific nested PCR (Polymerase Chain Reaction) primer pair (the sequence is as shown in SEQ ID NO.1-12) aiming at a rabbit BCR heavy chain (IgA / IgE / IgG / IgM) and a light chain (IgK / IgL). Through microfluid single-cell separation, nested PCR amplification and high-throughput sequencing, the naturally paired rabbit BCR full-length V (D) J sequence can be efficiently obtained. According to the rabbit-derived BCR sequence sequencing primer provided by the invention, B cell receptor library information of different tissue sources can be quickly and efficiently obtained. According to the method, paired antibody sequence information can be specifically obtained, B cell response diversity after rabbit immunization vaccine or pathogen infection can be better known, and important data support is provided for design, optimization, effect evaluation and the like of biological products.

This document provides methods and materials for assessing and / or treating subjects (e.g., humans) suspected of having cancer. For example, this document provides methods and materials for a nucleic acid sequence analysis which can determine a sequence of B cell receptor. In some cases, determining a sequence of B cell receptor (and, optionally, identifying the presence of one or more mutations and / or identifying the presence of aneuploidy) in DNA (e.g., cell-free DNA (cfDNA)) in a fluid sample (e.g., a cerebrospinal fluid sample) obtained from a subject (e.g., a human subject such as a human suspected of having cancer) can be used to identify the subject as having cancer.

The invention includes a chimeric autoantibody receptor (CAAR) specific for anti-acetylcholine receptor (AChR) B cell receptor (BCR), compositions comprising the CAAR, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant cells, e.g., T cells comprising the CAAR.

The application discloses a hepatitis B surface antigen specific B cell receptor gene knock-in mouse model, and establishes a hepatitis B virus surface antigen (HBsAg) specific B cell receptor (BCR) gene knock-in mouse model, wherein 70-90% of B cells of the mouse can specifically recognize HBsAg, and differentiate into germinal center B cells and plasma cells. Therefore, the model can be used for basic research on hepatitis B antiviral humoral immune response and tolerance mechanism, and can also be used for application research on development of drugs and vaccines for breaking HBsAg immune tolerance. In summary, the establishment of the model lays a solid foundation for development of a functional cure immune means for hepatitis B.

This invention provides EBV-susceptible 293T cells that simultaneously express the epidermal cell receptor EphA2 and the key protein RTA for lysis and replication, and EBV-susceptible BJAB cells that simultaneously express the B cell receptor CD21 and the key protein ZTA for lysis and replication, significantly enhancing the infectivity of these cells for EBV. The EBV infection titer of the cell lines of this invention is more than three times that of the normal control under the same conditions. These EBV-susceptible cells are of great significance for studying the mechanism of EBV infection, screening antiviral drugs, and developing vaccines.

Disclosed herein is a pipeline to identify variable chains (VCR), which encompass T cell receptors (TCRs) and B cell receptors (BCRs), that recognize epitopes in their low affinity using a bioinformatic statistical method with 10× data that encompasses both preprocessing and identification of antigen-specific VCRs. Also disclosed are methods for treating subjects having viral infections or cancer, the methods comprising administering antibodies from B cells transduced with antigen-specific BCRs and / or modified allogenic T cells transduced with antigen-specific TCRs identified through use of the pipeline.

The present disclosure relates to methods for testing the health of a subject's immune system and treating the subject based on the condition of the immune system. In particular, disclosed herein is a method comprising the steps of obtaining a sample of blood from the subject, reverse transcribing DNA from RNA in the sample; amplifying all seven chains of T and B cell receptors in the DNA sample using multiplex PCR to form amplicons; sequencing the amplicons to generate a sequencing library; identifying nodetypes, clonotypes, v genes, d genes, and j genes and corresponding read counts in the sequencing library; performing the foregoing steps using two or more healthy samples to form a consensus reference pool; identifying the number of nodetypes associated with each V gene sequence in the consensus reference pool and in the subject's sequencing library; comparing the number of nodetypes for each V gene in the consensus reference pool and the subject's sequencing library; and treating the subject if the number of nodetypes is significantly less than the number of nodetypes for V genes in the consensus reference pool. The disclosed method is able to identify gaps in an individual's immune system and treat that individual to improve the diversity of the individual's immune response.

The application discloses a kind of for preventing Bungowenia virus Polyepitope fusion protein, gene, vaccine and preparation method thereof, belong to biological medicine technical field.The Polyepitope fusion protein for preventing Bungowenia virus provided in the application is obtained in series by E. coli outer membrane anchoring protein ClyA, four MHC I class restricted T cell epitopes, four MHC II class restricted T cell epitopes, two B cell epitopes and BALB / c mouse immunoglobulin Fc fragment.The vaccine of the application is prepared by high-pressure homogenization process to obtain the engineered artificial nanovesicle (E-aBNV) with high-density surface display antigen array.The E-aBNV utilizes itself pathogen-associated molecular pattern to provide "self-adjuvant" effect, can efficiently activate B cell receptor and promote antigen cross-presentation, thereby synergistically inducing high level of neutralizing antibody and Th1-biased cellular immunity, which can effectively block the infection of Bungowenia virus to host cell.

The invention includes a chimeric autoantibody receptor (CAAR) specific for anti-muscle-specific kinase (MuSK) B cell receptor (BCR), compositions comprising the CAAR, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant cells comprising the CAAR.

The present invention provides affinity matured recombinant monoclonal antibodies (mAbs) and fragments that bind specifically to an HLA-E- peptide complex, including HLA-E-VL9 complexes, and regulate the cytotoxicity effector cell function of NK. Herein, monoclonal antibodies were recombinantly derived from isolated functional HLA-E-VL9-specific mAbs from the naïve human B cell repertoire. Such antibodies are capable of regulating effector cell cytotoxicity and can preferentially recognize HLA-E-VL9 peptide complexes expressed on the surface of tumor cells. The monoclonal antibodies were subject to one or more rounds of affinity maturation. The invention provides methods for using affinity matured HLA-E-VL9 mAbs to modulate NK cell function as part of immunotherapeutic strategies.

The invention relates to a single-cell multi-omics detection kit and application thereof. According to the single-cell multi-omics detection kit designed by the invention, a single-chain cell nucleic acid label with template conversion and connection capabilities is utilized, so that RNA and DNA in the same cell can be subjected to cell labeling at the same time, the cost is controllable, the process is simple, the kit has the characteristic of high throughput, thousands of single cells can be detected at the same time, and in addition, the kit has a good application prospect. By utilizing 5'transcriptome characteristics, variable VDJ information containing T / B cell receptors and gRNA sequence information can be synchronously analyzed, and the molecular action mechanism of cells can be analyzed in more omics modes.

The invention discloses a tumor nano vaccine for targeting B cells as well as a preparation method and application of the tumor nano vaccine. According to the tumor vaccine, on the basis of tumor cell membrane vesicles retaining tumor antigens, oligonucleotide of an immunologic adjuvant CpG motif and an anti-CD40 antibody are modified on the vesicles through a small molecule chemical cross-linking agent, and the tumor nano vaccine is obtained. According to the vaccine, an activation signal is provided for a B cell through combination of an antigen and a B cell receptor, combination of CpG and a Toll-like receptor and combination of an anti-CD40 antibody and CD40. According to the tumor nano vaccine, on one hand, the immune response of anti-tumor cells can be promoted by enhancing the antigen presentation capability of B cells; on the other hand, B cells can be induced to be differentiated into plasma cells, tumor antigen specific antibodies are secreted, and anti-tumor humoral immune response is mediated. The tumor vaccine disclosed by the invention can be used for comprehensively activating anti-tumor immune response and has a good application prospect in tumor treatment.

Disclosed herein include systems, methods, compositions, and kits for immune repertoire profiling. There are provided, in some embodiments, primer panels enabling the determination of the nucleotide sequence of the complete variable region of nucleic acids encoding mouse B cell receptor (BCR) and T cell receptor (TCR) polypeptides. In some embodiments, the method comprises single cell transcriptomic analysis.

Provided herein are methods for determining a sequence of a double stranded DNA molecule of an immune cell receptor (e.g., T cell receptor, B cell receptor).

The present invention relates to methods and compositions for engineering B cells to express transgenic B cell receptor (BCR) for antigen-induced antibody secretion, compositions, methods and uses thereof in immunotherapy.

The invention relates to compositions and methods for chimeric autoantibody recipient cells of acetylcholine receptors. The present invention includes chimeric autoantibody receptors (CAARs) having specificity against acetylcholine receptor (AChR) B cell receptor (BCR), compositions comprising the CAARs, polynucleotides encoding the CAARs, vectors and recombinant cells comprising the polynucleotides encoding the CAARs, e.g., T cells comprising the CAARs.

The invention provides a mandarin fish infectious spleen and kidney necrosis virus multi-antigen display vaccine based on a ferritin nanoparticle platform and a preparation method of the mandarin fish infectious spleen and kidney necrosis virus multi-antigen display vaccine, the vaccine utilizes the self-assembly characteristic of helicobacter pylori ferritin to fuse three key antigens MCP, MEP and ORF093R to the C end of a ferritin H chain to form a spherical nanoparticle with the diameter of about 12 nanometers, and the mandarin fish infectious spleen and kidney necrosis virus multi-antigen display vaccine can be used for preparing the mandarin fish infectious spleen and kidney necrosis virus multi-antigen display vaccine. 24 copies of virus antigens are displayed on the surface in a high-density mode, the nanoparticle vaccine remarkably enhances the crosslinking efficiency of a B cell receptor and activates strong body fluid and cellular immune response through high-density antigen display, and animal protection tests show that the relative protection rate of the trivalent nanoparticle vaccine reaches 94.1% and is far higher than that of a traditional monovalent vaccine. The vaccine has the advantages of strong immunogenicity, good safety, good stability and the like, and provides an innovative technical solution for prevention and control of ISKNV infection in aquaculture industry.

The invention provides a method for constructing a B cell receptor immune repertoire. The method comprises the following steps: S1, obtaining a tissue sample, preparing a single-cell suspension, obtaining a target B cell subset through flow cytometry sorting, and sorting the B cell subset into a lysis solution to obtain a cell lysis solution; s2, carrying out reverse transcription reaction on the cell lysis solution to obtain cDNA (complementary deoxyribonucleic acid); s3, carrying out PCR (Polymerase Chain Reaction) amplification on the cDNA in the S2 by adopting a specific primer, and purifying to obtain an amplification product; and S4, carrying out terminal filling-in modification, Adapter connection and purification on the amplification product in the S3 to obtain the B cell receptor immune repertoire. The invention provides a method for constructing a B cell receptor immune repertoire under the condition of extremely low initial cell quantity, the limitation that the prior art generally depends on a large number of initial cells is broken through, and the applicability of BCR sequencing in clinic and transformation medicine is remarkably improved.